This is an English translation of the Company s immediate report in Hebrew that was published on December 20, 2023 [Reference no.: 2023-01-138420. This English version is only for.
Enables financial services firm to operationalize MITRE ATT&CK with Splunk and eliminate detection coverage gaps based on organizational risk and priorities.
New renovation of the Davidson Center in Jerusalem utilizes interactive tech and augmented reality to highlight history and archaeology of Temple-era Jerusalem
Calgary, Alberta (Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome